Guide to EPA (Omega-3)

WRITTEN BY

Updated: 05/22/2025|12 min read

Summary

Eicosapentaenoic acid (EPA) is an omega-3 fatty acid found mainly in fatty fish and fish and algae oil supplements. Your body uses EPA to make molecules that affect blood flow, immune function, and how your cells communicate with each other.

Why It Matters

EPA helps produce compounds that regulate inflammation by competing with omega-6 fatty acids in inflammatory pathways. DHA and EPA work together to promote a balanced inflammatory state, each playing distinct but complementary roles.

EPA helps prevent clotting and supports healthy blood flow in your blood vessels. It also helps regulate mood and reduce neuroinflammation in your brain, which may provide a protective effect against cognitive decline, Alzheimer's disease, and mood disorders. EPA also helps protect your heart by reducing triglycerides and supporting healthy blood vessel function.

EPA is highly responsive to diet and supplements, making it a good indicator of both current omega-3 intake and inflammation status.

Associated Symptoms

EPA levels themselves are laboratory findings rather than medical conditions. However, EPA status may be associated with certain health conditions, each with its own symptoms.

Common symptoms that may indicate conditions associated with low EPA:

Chronic inflammatory disorders: Joint pain and stiffness, increased inflammatory markers
Mood disorders: Depression, anxiety, mood instability (EPA is being studied for its role in brain health)
Cardiovascular conditions: Elevated triglycerides, endothelial dysfunction
Skin conditions: Dryness, eczema, psoriasis
Stress-related disorders: Poor stress resilience, heightened stress response

Conditions potentially associated with high EPA (rare, usually from excessive supplementation):

Digestive disturbances: Loose stools, nausea, fishy aftertaste (usually from poor quality supplements)
Medication interactions: Enhanced effects of blood thinners or antiplatelet medications

It's important to understand that the relationship between EPA and these conditions is complex and sometimes bidirectional. While low EPA may contribute to these conditions, some of these conditions may also affect EPA absorption or metabolism. Many of these symptoms can result from numerous other factors, so they should be evaluated in the context of your overall health profile and other test results.

Clinical Ranges

Lab Reference Range: 0.2-2.3 % by wt

Lifestyle Factors That Can Impact It

Activities that increase EPA levels include:

Regular fatty fish consumption directly provides EPA.
Cold-water fish oils offer concentrated EPA.

Activities that decrease EPA levels include:

A high omega-6 diet competes with EPA use.
Excessive alcohol use impairs EPA absorption

Other Factors That Can Impact It

Medical Conditions

Diabetes: may lower levels by altering fat metabolism
Liver disease: may reduce levels by impairing fat processing
Digestive disorders: decrease absorption of EPA from food
Inflammatory conditions: can raise the intake requirement

Medications

Blood thinners: don't change levels but increase EPA's blood-thinning effects
Statins: may impact EPA levels by affecting fat metabolism
Orlistat (Xenical, Alli) can also block absorption

Testing Accuracy and Stability

Since EPA levels can change relatively quickly with diet and supplement changes, proper timing and preparation are essential for accurate assessment.

Factors That Can Affect Your Test Results

Recent meals with fatty fish can increase levels
Levels may be lower when fasting

How it Relates to Other Markers

EPA's interactions with other biomarkers can also provide your doctor clues into your overall health status. Key related markers include:

Docosahexaenoic acid (DHA): DHA and EPA are often consumed together in fatty fish.
Docosapentaenoic acid (DPA): DPA serves as an omega-3 reservoir that can increase EPA levels when needed.
Triglycerides: High levels may indicate problems with fat metabolism that can lower EPA.
Vitamin D: Low levels can reduce EPA effectiveness.

Follow-up Considerations

If your EPA levels are low, your healthcare provider may recommend supplements, diet changes, and retesting your levels to see if they respond to any interventions. Any further testing will depend on your level and overall health. You should always speak to your doctor if you have medical questions or before making medical decisions.

When Re-Testing May be Appropriate

Normal levels: Every 6--12 months
Low levels: Every 3 months until normalized
During supplementation: Every 3--4 months
Inflammatory conditions: Monthly until stable
Mental health treatment: Every 2--3 months

Additional Testing Your Doctor May Consider

Complete omega-3 panel
Cardiovascular risk markers
Oxidative stress markers

When Additional Care May be Warranted

Persistently low levels despite supplementation
High inflammation with low EPA
Cardiovascular symptoms
Mood disorders not improving
Multiple fatty acid imbalances

Bibliography

References

1. Calder, Philip C. "Marine Omega-3 Fatty Acids and Inflammatory Processes: Effects, Mechanisms and Clinical Relevance." Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1851, no. 4, 2015, pp. 469--484. DOI: 10.1016/j.bbalip.2014.08.010.

2. Mozaffarian, Dariush, and Jason H.Y. Wu. "Omega-3 Fatty Acids and Cardiovascular Disease: Effects on Risk Factors, Molecular Pathways, and Clinical Events." Journal of the American College of Cardiology, vol. 58, no. 20, 2011, pp. 2047--2067. DOI: 10.1016/j.jacc.2011.06.063.

3. Kris-Etherton, Penny M., et al. "Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease." Circulation, vol. 106, no. 21, 2002, pp. 2747--2757. DOI: 10.1161/01.CIR.0000038493.65177.94.

4. Tavazzi Luigi, et al. "Effect of n-3 Polyunsaturated Fatty Acids in Patients with Chronic Heart Failure (the GISSI-HF Trial): A Randomised, Double-Blind, Placebo-Controlled Trial." The Lancet, vol. 372, no. 9645, 2008, pp. 1223--1230. DOI: 10.1016/S0140-6736(08)61239-8.

5. Mori, Trevor A., and Lawrence J. Beilin. "Omega-3 Fatty Acids and Inflammation." Current Atherosclerosis Reports, vol. 6, no. 6, 2004, pp. 461--467. DOI: 10.1007/s11883-004-0087-5.

6. Ruxton, C.H.S., et al. "The Impact of Long-Chain n-3 Polyunsaturated Fatty Acids on Human Health." Nutrition Research Reviews, vol. 18, no. 1, 2005, pp. 113--129. DOI: 10.1079/NRR200497.

7. Simopoulos, Artemis P. "The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases." Experimental Biology and Medicine, vol. 233, no. 6, 2008, pp. 674--688. DOI: 10.3181/0711-MR-311.

8. Yokoyama, Mitsuhiro, et al. "Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): A Randomised Open-Label, Blinded Endpoint Analysis." The Lancet, vol. 369, no. 9567, 2007, pp. 1090--1098. DOI: 10.1016/S0140-6736(07)60527-3.

9. Harris, William S., and Clemens von Schacky. "The Omega-3 Index: A New Risk Factor for Death from Coronary Heart Disease?" Preventive Medicine, vol. 39, no. 1, 2004, pp. 212--220, doi:10.1016/j.ypmed.2004.02.030.

10. Innes, Jacqueline K., and Philip C. Calder. "Marine Omega-3 (n-3) Fatty Acids for Cardiovascular Health: An Update for 2020." International Journal of Molecular Sciences, vol. 21, no. 4, 2020, p. 1362, doi:10.3390/ijms21041362.

11. Martins, Julian G. "EPA but Not DHA Appears to Be Responsible for the Efficacy of Omega-3 Long Chain Polyunsaturated Fatty Acid Supplementation in Depression: Evidence from a Meta-analysis of Randomized Controlled Trials." Journal of the American College of Nutrition, vol. 28, no. 5, 2009, pp. 525--542, doi:10.1080/07315724.2009.10719785.